Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). (Q39006241)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 January 2017

Language	Label	Description	Also known as
English	Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).	scientific article published on 23 January 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Torbjörn Tomson

5

object named as

Torbjörn Tomson

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

4

object named as

Emilio Perucca

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Svein I Johannessen

2

object named as

Svein I Johannessen

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Meir Bialer

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

René H Levy

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

H Steve White

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

23 January 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

181-221

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII).

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Adenosinergic signaling in epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Seizure suppression by adenosine-releasing cells is independent of seizure frequency

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Adenosine kinase: exploitation for therapeutic gain

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Upregulation of adenosine kinase in astrocytes in experimental and human temporal lobe epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Neuroactive steroids for the treatment of status epilepticus

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Pharmacokinetic and behavioral effects of allopregnanolone in healthy women

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Effects of allopregnanolone on sedation in men, and in women on oral contraceptives

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Use of epileptic animals for adverse effect testing

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Brivaracetam augments short-term depression and slows vesicle recycling

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cation-chloride cotransporters in neuronal development, plasticity and disease

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

A novel prodrug-based strategy to increase effects of bumetanide in epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Structure-activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of the human NKCC2A transporter

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Quantitation of Na+-K+-2Cl- cotransport splice variants in human tissues using kinetic polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Characteristics of the cation cotransporter NKCC1 in human brain: alternate transcripts, expression in development, and potential relationships to brain function and schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cannabinoids for epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Molecular Targets of Cannabidiol in Neurological Disorders

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cannabidivarin is anticonvulsant in mouse and rat.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Distinct behavioral phenotypes in novel "fast" kindling-susceptible and "slow" kindling-resistant rat strains selected by stimulation of the hippocampal perforant path

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

2-Deoxy-d-Glucose (2-DG)-Induced Cardiac Toxicity in Rat: NT-proBNP and BNP as Potential Early Cardiac Safety Biomarkers

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Behavioral, cognitive, and safety profile of 2-deoxy-2-glucose (2DG) in adult rats

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

mTOR inhibitors as a new therapeutic option for epilepsy.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Rapamycin is a neuroprotective treatment for traumatic brain injury.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Evaluation of development-specific targets for antiepileptogenic therapy using rapid kindling

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Single-channel activity of the Ca2+-dependent K+ channel is modulated by FK506 and rapamycin

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

A role for the mTOR pathway in surface expression of AMPA receptors.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Clinical pharmacokinetics of everolimus

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Therapeutic Drug Monitoring of Everolimus: A Consensus Report.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Pharmacokinetics of fenfluramine enantiomers in man

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Successful use of fenfluramine as an add-on treatment for Dravet syndrome

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Pharmacokinetics of huperzine A following oral administration to human volunteers

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

A phase II trial of huperzine A in mild to moderate Alzheimer disease

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Minocycline inhibits brain inflammation and attenuates spontaneous recurrent seizures following pilocarpine-induced status epilepticus

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Minocycline exerts acute inhibitory effects on cerebral cortex excitability in humans

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Open-label add-on treatment trial of minocycline in fragile X syndrome

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Anticonvulsant neuropeptides as drug leads for neurological diseases

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Anticonvulsant activity of a nonpeptide galanin receptor agonist

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Neuroactive steroids differ in potency but not in intrinsic efficacy at the GABA(A) receptor in vivo

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

sec-Butylpropylacetamide (SPD) has antimigraine properties

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus.

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Key factors in the discovery and development of new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1111%2FEPI.13634

21 January 2018

Identifiers

10.1111/EPI.13634

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39006241&oldid=1695993820"